Equity research analysts tracking X4 Pharmaceuticals (XFOR) maintain optimistic 12-month average price targets clustering around $11.60, representing substantial potential percentage upside from its current trading value. Forecast models project strong double-digit revenue growth driven by commercial expansion and clinical milestones, though ongoing research expenditures and dilution risks remain factors monitored closely by market participants.